Home Newsfeeds Credit Suisse Maintains Outperform on UiPath, Maintains $27.5 Price Target

Credit Suisse Maintains Outperform on UiPath, Maintains $27.5 Price Target

Credit Suisse analyst Sami Badri maintains UiPath (NYSE:PATH) with a Outperform and maintains $27.5 price target.

byBenzinga Newsdesk

March 17, 2023

1 minute read

Credit Suisse analyst Sami Badri maintains UiPath (NYSE:PATH) with a Outperform and maintains $27.5 price target.

Analyst Ratings

Expert Ratings for Spotify Technology

By Benzinga Insights

October 7, 2:05 PM

Within the last quarter, Spotify Technology (NYSE:SPOT) has observed the following analyst ratings:

SPOT

Investor Sentiment Declines, Dow Falls For Second Session

By Avi Kapoor

April 3, 5:23 AM

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed lower on Tuesday, with the Dow Jones index recording losses for the second straight session. The 30-stock Dow also recorded its worst day since March 5.

AYI

News

AST SpaceMobile Completes Deployment Of Communications Array For Its BlueWalker 3 Test Satellite In Orbit

By Bill Haddad

November 14, 8:15 AM

AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ:ASTS), the company building the first and only space-based cellular broadband network accessible directly by standard mobile phones, announced today

ASTS

M&A
News

HDL Therapeutics Inc Plans To Become Publicly Traded Via A Business Combination With $225M Swiftmerge With Goal To Transform Cardiovascular Disease Treatment

By Happy Mohamed

April 24, 1:31 PM

IVCP Swiftmerge Acquisition Corp ("Swiftmerge"), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a

IVCP

Credit Suisse Maintains Outperform on UiPath, Maintains $27.5 Price Target

Related Posts

Expert Ratings for Spotify Technology

Investor Sentiment Declines, Dow Falls For Second Session

AST SpaceMobile Completes Deployment Of Communications Array For Its BlueWalker 3 Test Satellite In Orbit

HDL Therapeutics Inc Plans To Become Publicly Traded Via A Business Combination With $225M Swiftmerge With Goal To Transform Cardiovascular Disease Treatment